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Emerging findings suggest the existence of a cross-talk between hypocretinergic and
endocannabinoid systems. Although few studies have examined this relationship, the
apparent overlap observed in the neuroanatomical distribution of both systems as well
as their putative functions strongly point to the existence of such cross-modulation.
In agreement, biochemical and functional studies have revealed the existence of
heterodimers between CB1 cannabinoid receptor and hypocretin receptor-1, which
modulates the cellular localization and downstream signaling of both receptors. Moreover,
the activation of hypocretin receptor-1 stimulates the synthesis of 2-arachidonoyl
glycerol culminating in the retrograde inhibition of neighboring cells and suggesting
that endocannabinoids could contribute to some hypocretin effects. Pharmacological
data indicate that endocannabinoids and hypocretins might have common physiological
functions in the regulation of appetite, reward and analgesia. In contrast, these
neuromodulatory systems seem to play antagonistic roles in the regulation of sleep/wake
cycle and anxiety-like responses. The present review attempts to piece together what
is known about this interesting interaction and describes its potential therapeutic
implications.
Keywords: hypocretinergic system, endocannabinoid system, heteromerization, reward, energy balance,
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ENDOCANNABINOIDS AND HYPOCRETINS: TWO
ESSENTIAL NEUROMODULATORS
The extracts of the plant Cannabis sativa contain about 60
active compounds of which 9-tetrahydrocannabinol (THC) is
the main psychoactive component (Hall and Degenhardt, 2009).
Although it was initially believed that THC exerted its effects by
interacting with the plasma membrane due to its high lipophilic
nature (Martin, 1986), the site of action of this substance is
an endogenous neuromodulatory system termed endogenous
cannabinoid system. The endocannabinoid system is constituted
by membrane receptors, their fatty-acid derived endogenous lig-
ands and the enzymatic machinery that synthesizes and degrades
these lipidic neurotransmitters.
At least two different cannabinoid receptors have been cloned,
termed CB1 and CB2 receptors, which share only 44% amino acid
(AA) sequence homology (Matsuda et al., 1990; Munro et al.,
1993). The distribution of CB1 and CB2 is markedly different:
CB1 is the most abundant G-protein coupled receptor (GPCR)
in the central nervous system (CNS) (Herkenham et al., 1990),
while CB2 is mainly found in immune cells and peripheral tissues
(Munro et al., 1993), although some CB2 expression is detected
in the brainstem, cortex and cerebellar neurons and microglia
(Núñez et al., 2004; Van Sickle et al., 2005). In addition, cannabi-
noid compounds are able to activate other “non-CB” recep-
tors, such as GPR55, peroxisome proliferator-activated receptors
(PPARs), and vanilloid type TRP channels (Pertwee et al., 2010;
Kukkonen, 2011).
Endocannabinoids are arachidonic acid-containing
messengers generated by phospholipase action, produced
on demand at the site of need and are not usually stored
in vesicles like classical neurotransmitters (Di Marzo,
2009). The most important endocannabinoids identified
are N-arachidonylethanolamine (anandamide) and 2-
arachidonylglycerol (2-AG) (Devane et al., 1992; Sugiura
et al., 1995), although other ligands such as noladin ether and
virodhamide have also been detected (Hanus et al., 2001; Porter
et al., 2002). Endocannabinoids are known to act as retrograde
regulators of synaptic transmission. Thus, after being synthesized
in postsynaptic neurons in response to a depolarization-induced
increase in intracellular Ca2+, and released to act on CB1
expressed in presynaptic and/or nearby neurons, endocannabi-
noids attenuate presynaptic depolarization and subsequent
neurotransmitter release (Kano et al., 2009). After synthesis and
release, endocannabinoid signaling is terminated by reuptake
into both neurons and glia followed by intracellular hydrolysis of
anandamide and 2-AG, carried out by fatty acid amide hydrolase
(FAAH) and monoacylglycerol lipase (MAGL), respectively
(Muccioli, 2010).
It has been extensively reported that the endocannabinoid
system reciprocally modulates other neurotransmitter systems.
The interaction with the endogenous opioid system is the most
explored of these cross-talks (Robledo et al., 2008; Parolaro et al.,
2010), but pharmacological and biochemical data also reveal
an interplay at both molecular and functional levels with other
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neurotransmitters, such as the dopaminergic and adenosinergic
systems (Carriba et al., 2007; Ferré et al., 2009; Fernández-Ruiz
et al., 2010). Interestingly, emerging evidence points to a cross-
modulation between endocannabinoid and hypocretinergic sys-
tems, providing a new range of potential therapeutic applications
to currently existing drugs targeting these systems.
Hypocretin-1/orexin-A and hypocretin-2/orexin-B are two
neuropeptides proteolytically cleaved from the same precursor,
prepro-hypocretin/prepro-orexin (de Lecea et al., 1998; Sakurai
et al., 1998). Hypocretin-1 is constituted by 33 AA and post-
translationally stabilized by two intrachain disulphide bonds,
whereas hypocretin-2 consists of 28 AA and remains as a linear
peptide (Sakurai et al., 1998). As other neuromodulatory pep-
tides, hypocretins are stored at the axon terminals within secre-
tory vesicles, which release their content in a Ca2+-dependent
manner (de Lecea et al., 1998). In contrast to endocannabi-
noids, hypocretins act mainly as neuroexcitatory modulators.
Hypocretins induce neuroexcitation at both pre- and postsy-
naptic levels: activation of presynaptic Ca2+ channels facilitates
neurotransmitter release (van den Pol et al., 1998; Li et al.,
2002), and regulation of diverse postsynaptic ion channels leads
to postsynaptic depolarization (Kukkonen et al., 2002). However,
few studies also report hypocretin-induced synaptic inhibition,
although the mechanisms underlying this effect remain unclear
(Davis et al., 2003; Ma et al., 2007).
So far, two hypocretin receptors with 64% AA sequence
homology have been identified: hypocretin or orexin receptor-
1 (HcrtR1/OxR1) and hypocretin or orexin receptor-2
(HcrtR2/OxR2) (Sakurai et al., 1998). HcrtR1 displays a
10-fold higher affinity for hypocretin-1 than hypocretin-2,
whereas HcrtR2 has equal affinity for both peptides (Smart et al.,
2001; Ammoun et al., 2003). Hypocretin-expressing neurons are
located exclusively in the hypothalamus, especially in the lateral
(LH), perifornical (PFA), and dorsomedial areas (DMH) (de
Lecea et al., 1998; Peyron et al., 1998; Sakurai et al., 1998). Despite
representing a relatively small population of cells, hypocretinergic
neurons send projections widely through the entire neuroaxis
of the CNS (Peyron et al., 1998), suggesting that hypocretins
modulate the activity of multiple neurotransmitter systems and
therefore regulate diverse physiological functions.
COMMON CHARACTERISTICS BETWEEN
ENDOCANNABINOID AND HYPOCRETINERGIC SYSTEMS
Anatomical studies have found that CB1 and HcrtRs show an
overlapping distribution in several areas of the CNS (Hervieu
et al., 2001; Marcus et al., 2001; Mackie, 2005), suggesting a
common role in some physiological functions (Figure 1). Thus,
HcrtR1 and HcrtR2, as well as CB1, are widely expressed within
the entire hypothalamus, denoting an important function of these
systems in energy homeostasis and central regulation of neu-
roendocrine and autonomic functions (Wittmann et al., 2007;
Tsujino and Sakurai, 2009). Both receptors are also found in
diverse areas of the mesocorticolimbic system, such as the ven-
tral tegmental area (VTA), the nucleus accumbens (NAc), the
prefrontal cortex (PFC), the septal nuclei and the amygdaloid
nuclei, supporting the regulation of natural reward and addic-
tion processes by endocannabinoid and hypocretinergic systems
(Maldonado et al., 2006; Aston-Jones et al., 2010; Plaza-Zabala
et al., 2012). The presence of CB1, HcrtR1, and HcrtR2 within
diverse brainstem nuclei, including the raphe nuclei, the locus
coeruleus, the reticular formation and the periaqueductal gray
(PAG), is in agreement with the role of these neuromodulators
with the regulation of anxiety-like responses, sleep/wake cycle and
nociception (Eriksson et al., 2010; Häring et al., 2012; Wilson-
Poe et al., 2012). Nevertheless, the existence of cross-reactivity
problems with HcrtR antibodies has hindered the precise location
of these receptors (Kukkonen, 2012). Hence, although specific
CB1 expression among different neuronal populations has been
well characterized (Mackie, 2005), the location of HcrtRs is cer-
tainly known only at the level of brain structure since it has been
confirmed by in situ hybridization studies (Hervieu et al., 2001).
As a consequence, direct synaptic connections between CB1 and
HcrtRs are not well defined. On the other hand, recent studies
have detected certain multifocal expression of CB2 in the brain at
levels much lower than those of CB1 receptors (Gong et al., 2006;
Onaivi et al., 2006). Among these CB2 expression foci, hippocam-
pus, amygdala and PAG are potentially the most relevant areas to
the study of the cannabinoid-hypocretinergic interplay.
CB1 and CB2, as well as HcrtR1 and HcrtR2, belong to
the rhodopsin subfamily of GPCR superfamily. The cellular sig-
nals triggered upon cannabinoid receptor activation differ from
those initiated following the stimulation of hypocretin receptor.
However, it seems that diverse signaling pathways are common for
cannabinoid and hypocretin receptors (Demuth and Molleman,
2006) (Figure 2). Both CB1 and CB2 receptors are associated with
the Gi/o family of G-proteins, as most cannabinoid effects are
blocked by pertussis toxin (PTX) (Howlett et al., 1986; Slipetz
et al., 1995). Subsequent functional inhibition of adenylyl cyclase
(AC) activity and decreased cAMP production has been observed
in most tissues and cells investigated (Howlett et al., 2002).
However, CB1 has been shown to stimulate AC when Gi protein
is hardly available, such as under PTX treatment or sequestering
by other GPCR receptor activation, indicating that CB1 may be
able to couple Gs under these particular experimental conditions
(Glass and Felder, 1997; Jarrahian et al., 2004). The modulation
of voltage-dependent ion channels by CB1 activation is thought to
underlie the cannabinoid-induced inhibition of neurotransmitter
release, although it seems that CB1-independent mechanisms of
ion channelmodulationmight also exist (Demuth andMolleman,
2006). CB1 activates inward-rectifying K+ (Kir) and A-type
K+ channels, triggering the plasmatic membrane repolarization
(Deadwyler et al., 1995; Vásquez et al., 2003). This was shown to
be mediated by CB1 receptor-mediated reduction in cAMP lev-
els and PKA activation (Deadwyler et al., 1995; Hampson et al.,
1995). Additionally, CB1 inhibits N-, P/Q- and L-type voltage-
gated Ca2+ channels, leading to a decrease in Ca2+ influx, mostly
by direct Gβγ interaction with the channel (Howlett et al., 2002).
CB1 and CB2 activation also leads to the phosphorylation and
activation of the MAP kinase cascade (Bouaboula et al., 1995,
1997; Derkinderen et al., 2001), which regulates neuronal gene
expression and synaptic plasticity. Diverse transduction path-
ways leading to activation of different MAP kinases (ERK1/2,
JNK, ERK5, and p38) have been proposed, depending on the
cell type and the stimulus. MAP kinase activation is mediated
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FIGURE 1 | Schematic representation of the main areas expressing
CB1, HcrtR1 and HcrtR2 in the mouse brain and location of
hypocretinergic neurons. (A) CB1 receptor distribution. (B) HcrtR1
and HcrtR2 distribution and localization of hypocretinergic neurons.
A4, A5, A7, pons cell groups; AMG, amygdala; CPu, caudate
putamen; Ctx, cortex; DCN, deep cerebellar nuclei; DRN, dorsal
raphe nucleus; GP, globus pallidus; LC, locus coeruleus; NAc, nucleus
accumbens; NTS, nucleus of the solitary tract; OB, olfactory bulb;
OT, olfactory tubercle; PAG, periaqueductal gray; PVT, paraventricular
nucleus of thalamus; SNc, substantia nigra pars compacta; SNr,
substantia nigra pars reticulata; TMN, tuberomammillary nucleus; VTA,
ventral tegmental area.
by PI3K pathway in CHO cells (Galve-Roperh et al., 2002), PC-
3 cells (Sánchez et al., 2003) and astrocytoma cells (Gómez del
Pulgar et al., 2000), through the protein kinase B (PKB/Akt) phos-
phorylation and Raf-1 activation. Some studies also suggest that
decrease in cAMP levels, and consequently reduced inhibitory
c-Raf phosphorylation by PKA activity, may participate in the
stimulatory effects of CB1 activation on the MAP kinase pathway
(Melck et al., 1999; Davis et al., 2003).
On the other hand, both hypocretin receptors are coupled to
Gq proteins, which induce the activation of PLC and produc-
tion of the second messengers DAG and IP3 from PIP2. This
triggers the activation of PKC, which phosphorylates and mod-
ulates effector ion channels leading to Ca2+ entrance (van den
Pol et al., 1998; Eriksson et al., 2001), as well as further IP3-
mediated entry via store-operated Ca2+ channels (Kukkonen and
Akerman, 2001; Larsson et al., 2005). In addition, membrane
depolarization is facilitated by activation of Na+/Ca2+ exchanger
(Burdakov et al., 2003), increase of non-selective cation chan-
nel conductances (Liu et al., 2002; Yang and Ferguson, 2002;
Murai and Akaike, 2005) and/or blockade of Kir channels (Hwang
et al., 2001; Yang and Ferguson, 2003; Ishibashi et al., 2005). It
remains to be further elucidated by using selective antagonists
the identification of the receptor subtype mediating these effects.
Additionally, some studies of lipid signaling pathways activated by
HcrtR1-expressing CHO cells have also revealed coupling to PLD
and PLA2 (Turunen et al., 2012). Besides, stimulation of both
hypocretin receptors has been suggested to modulate AC activ-
ity by coupling other G-proteins, such as Gs-protein as shown by
AC activation and cAMP production in neurons (Gorojankina
et al., 2007) and astrocytes (Woldan-Tambor et al., 2011), or
Gi-protein as observed by hypocretin-1 inhibition of AC via Gi-
coupling (Holmqvist et al., 2005; Urban´ska et al., 2012). Similar
to cannabinoids, hypocretin signaling also activates the MAP
kinase pathway. Thus, HcrtR1 challenge leads to ERK1/2 and p38
kinase phosphorylation (Ammoun et al., 2006a). Downstream
effectors contributing to ERK1/2 activation after HcrtR1 stimu-
lation include at least Ca2+ influx, PLC/PKC, Ras, Src, and PI3K
(Ammoun et al., 2006b). Similar results have been recorded in
an HcrtR2 expression system (Tang et al., 2008). Thus, cannabi-
noid and hypocretinergic signaling differ in their modulation of
ion channel currents and AC activity, while they converge in the
activation of the MAP kinase pathway.
MOLECULAR INTERACTIONS BETWEEN CB1 AND HcrtR1
Direct CB1-HcrtR1 interaction was first proposed in 2003
(Hilairet et al., 2003). Indeed, a 100-fold increase in the potency
of hypocretin-1 to activate the ERK signaling was observed when
CB1 and HcrtR1 were co-expressed in CHO cells. This effect
required a functional CB1 receptor as evidenced by the block-
ade of hypocretin response by the CB1 antagonist rimonabant,
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FIGURE 2 | Overview of the main synaptic signaling mechanisms of
endocannabinoid and hypocretinergic systems. (A)
Endocannabinoid-mediated synaptic signaling. (1) Glutamate is released from
presynaptic terminals and stimulates both ionotropic and metabotropic
glutamate receptors, leading to postsynaptic depolarization through
Ca2+entrance and Gq-protein activation. (2) High Ca2+ concentration
stimulates endocannabinoid synthesis through PLC and PLD. 2-AG synthesis
is also mediated by Gq-protein activation. (3) Endocannabinoids are released
to the synaptic cleft and activate CB1 and CB2 presynaptic receptors. Some
of the main downstream consequences of CB receptor activation and
subsequent Gi-protein stimulation are: (3a) inhibition of AC activity, (3b)
membrane hyperpolarization after modulation of K+ and Ca2+ channels, and
subsequent inhibition of NT release, (3c) activation of protein kinase
cascades such as MAPK pathway. (B) Hypocretin-mediated synaptic
signaling. (1) Hypocretins are released from presynaptic terminals and
activate postsynaptic HcrtR1 and HcrtR2. (2) HcrtR stimulation is mainly
associated with Gq-protein activation, but it can activate also other G-protein
subtypes. Some of the main downstream consequences of HcrtR activation
and subsequent Gq-protein stimulation are: (2a) activation of PLC activity, and
subsequent DAG and 2-AG synthesis (2b) membrane depolarization after
modulation of K+ channels, non-specific cationic channels and
Na+/Ca2+exchanger, (2c) activation of protein kinase cascades such as MAPK
pathway. NT, neurotransmitter; iGluR, ionotropic glutamate receptor; mGluR,
metabotropic glutamate receptor; PIP2, phosphatidylinositol bisphosphate;
DAG, diacylglicerol; 2-AG, 2-arachidonoylglycerol; NAPE,
N-arachidonoyl-phosphatidylethanolamine; AEA, anandamide; PLC,
phospholipase C; DAGL, diacylglycerol lipase; PLD, phospholipase D; AC,
adenyl cyclase; cAMP, cyclic AMP; MAPK, mitogen-activated protein kinase;
Hcrt-1, hypocretin-1; Hcrt-2, hypocretin-2; PKC, protein kinase C; X+,
unspecific cation.
and was blocked by PTX, suggesting a Gi-mediated potentia-
tion. Based on electron microscopy colocalization, the authors
inferred the formation of heteromeric complexes by HcrtR1 and
CB1 that might explain the enhancement in hypocretin-induced
ERK signaling (Hilairet et al., 2003). Importantly, in these colocal-
ization studies specificity problems with anti-HcrtR1 antibodies
were avoided by tagging the N-terminus of HcrtR1 with the c-
Myc epitope, monitoring its expression using mouse monoclonal
anti-Myc antibodies. The possible existence of CB1-HcrtR1 het-
eromerization has been further assessed by co-expressing these
GPCRs in HEK293 cells (Ellis et al., 2006). In this study, rimona-
bant caused a decrease in the potency of hypocretin-1 to activate
the MAP kinases ERK1/2 in cells co-expressing both receptors.
Similarly, the HcrtR1 antagonist SB674042 reduced in these cells
the potency of the CB1 agonist WIN55,212-2 to phosphorylate
ERK1/2. Additionally, co-expression of CB1 and HcrtR1 resulted
in coordinated trafficking of these GPCRs. Indeed, following
inducible expression in HEK293 cells, HcrtR1 was mainly located
in the cell surface, while CB1 constitutive expression resulted
in a distribution pattern in intracellular vesicles consistent with
spontaneous, agonist-independent internalization. When both
receptors were co-expressed, HcrtR1 appeared to be recycled in
intracellular vesicles, adopting the location of CB1 inherent to this
model. When treated with rimonabant or with SB674042, both
CB1 and HcrtR1 were re-localized at the cell surface. The possi-
ble direct protein-protein interaction between CB1 and HcrtR1
deduced from these data was tested by performing single cell
fluorescence resonance energy transfer (FRET) imaging studies,
which confirmed that CB1 andHcrtR1 were close enough to form
veritable heteromers (Ellis et al., 2006). Recently, the same group
has demonstrated further evidence of such heteromerization by
covalently labeling the extracellular domains of CB1 and HcrtR1
with SNAP-tag® and CLIP-tag™ labeling systems, which consist
in two polypeptides that can be fused to a protein of interest and
further covalently tagged with a suitable ligand (i.e., a fluores-
cent dye), allowing a reliable monitorization of these heteromers
at the cell surface (Ward et al., 2011a,b). In this study, a higher
potency of hypocretin-1 to regulate CB1-HcrtR1 heteromer com-
pared with the HcrtR1-HcrtR1 homomer was reported (Ward
et al., 2011b). These data provide unambiguous identification of
CB1-HcrtR1 heteromerization, which has a substantial functional
impact.
Besides the heteromerization, an additional mechanism has
been proposed to explain the increase in the potency of
hypocretin-1 to activate the ERK pathway in the presence of
CB1 (Jäntti et al., 2013; Kukkonen and Leonard, 2013). Recent
studies report that HcrtR1-expressing CHO cells may release 2-
AG in response to hypocretin-1 stimulation. In these cells, the
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activation of PLC is responsible for DAG production, which in
turn is used by diacylglycerol lipase (DAGL) as a substrate for
2-AG production (Turunen et al., 2012). Taking into account
that both HcrtR1 and CB1 activate ERK upon ligand binding
(Bouaboula et al., 1995; Ammoun et al., 2006a), it is possi-
ble that 2-AG-mediated stimulation of CB1 could contribute to
increase the potency of hypocretin-1 signaling in the CHO cell
expression system. In addition, recent evidence supports that
endocannabinoids may act in an auto- or paracrine manner,
and the influence of endogenously produced endocannabinoids
when introducing Gq-coupled receptors to the expression sys-
tem cannot be discarded (Howlett et al., 2011). Indeed, it has
been demonstrated that HcrtR1 stimulation elevates 2-AG in bio-
logically relevant quantities, activating CB1 receptors in nearby
cells (Turunen et al., 2012). Importantly, this hypocretin-induced
endocannabinoid release might shed light on the mechanisms
by which hypocretins mediate synaptic inhibition in certain
conditions.
FUNCTIONAL INTERACTION BETWEEN CANNABINOIDS
AND HYPOCRETINS: EMERGING STUDIES
Despite anatomical, biochemical and pharmacological evidence
supporting the possible existence of a link between cannabinoids
and hypocretins, few studies have directly evaluated this cross-
talk at the functional level (Table 1). Current research suggests
their mutual involvement in the regulation of several physiolog-
ical responses including appetite, reward, sleep/wake cycle and
nociception.
APPETITE AND ENERGY BALANCE
The regulation of energy balance is determined by the control
of food intake and energy expenditure. The so-called homeo-
static control of energy balance is exerted in response to variations
in the nutritional status and energy stores and is autonomic or
involuntary, whereas the non-homeostatic control has a cognitive
component strongly influenced by the hedonic aspects of eat-
ing (Saper et al., 2002; Berthoud, 2007) (see section Regulation
of the brain rewarding system). Interestingly, endocannabinoid
and hypocretinergic systems appear to be involved in both pro-
cesses. Recently, the LH has been suggested to constitute a bridge
between homeostatic and non-homeostatic brain areas involved
in energy balance regulation. Indeed, this region connects the
hypothalamic regulators of energy balance [e.g., the arcuate
nucleus (Arc) and the paraventricular nucleus (PVN)], to the NAc
and the VTA, two key parts of the brain reward system (Berthoud,
2007; Richard et al., 2009).
Endocannabinoids, as well as systemic administration of
cannabinoid agonists, stimulate food intake (Williams et al., 1998;
Williams and Kirkham, 1999). These effects are mediated by CB1
receptor. Indeed, rimonabant reduces the consumption of stan-
dard food in food-deprived animals (Colombo et al., 1998), and
CB1-deficient mice consume less food than wild-type littermates
and are resistant to diet-induced obesity (Di Marzo et al., 2001;
Cota et al., 2003). Accordingly, fasting increases levels of anan-
damide and 2-AG in the limbic forebrain and, to a lesser extent,
of 2-AG in the hypothalamus, whereas feeding declines endo-
cannabinoid levels in these areas (Kirkham et al., 2002). Likewise,
central administration of hypocretin-1 or hypocretin-2 stimu-
lates food consumption, whereas systemic administration of the
HcrtR1 antagonist SB334867 reduces feeding (Sakurai et al., 1998;
Haynes et al., 2000; Shiraishi et al., 2000). Furthermore, prepro-
hypocretin mRNA is upregulated following fasting (Sakurai et al.,
1998) as well as in obese mice during food restriction (Yamanaka
et al., 2003). Interestingly, pretreatment with a non-anorectic
dose of rimonabant blocks orexigenic actions of hypocretin-1
administered by intracerebroventricular route (icv) in pre-fed
rats, suggesting that hypocretin-1 exerts its orexigenic action
through CB1 receptor activation (Crespo et al., 2008). However,
the increase induced by hypocretin-1 in food intake correlates
with an increase in locomotion and wakefulness (Yamanaka et al.,
1999; Crespo et al., 2008), leading to the hypothesis that the pri-
mary function of this system is promoting arousal in response to
food deprivation, which would facilitate the food consumption
(Yamanaka et al., 2003; Cason et al., 2010).
One of the main hypothalamic regulators of appetite is the
Arc-PVN axis (Girault et al., 2012) (Figure 3). Circulating lev-
els of leptin, produced by adipocytes in proportion to the
adipose mass, inhibit neurons in the Arc that co-express the
orexigenic neurotransmitters neuropeptide Y (NPY) and agouti-
related peptide (AgRP), whereas they activate the anorexic
pro-opiomelanocortin (POMC) neurons that co-express cocaine-
amphetamine-related transcripts (CART). Grehlin, released dur-
ing fasting, produces the opposite effect on these neurons.
NPY/AgRP and POMC/CART neurons convey their informa-
tion to second-order neurons in the PVN and LH, such as
the corticotrophin-releasing hormone (CRH), the melanin-
concentrating hormone (MCH) and hypocretin neurons (Elias
et al., 1998). Emerging evidence suggests that NPY and hypocre-
tin neurons have reciprocal excitatory connections. Thus, reduced
plasma glucose and leptin and increased grehlin levels induce
fasting-related arousal by causing an activation of NPY neurons
finally increasing the firing of hypocretin neurons. Additionally,
it seems that increased hypocretinergic activity during sleep
deprivation may activate NPY neurons resulting in hyperphagia
independent from peripheral endocrine and metabolic signaling
(Yamanaka et al., 2000).
CB1 receptors colocalize with CART, MCH and hypocretin
neurons (Cota et al., 2003). Acute administration of rimonabant
induces c-fos in all these neuronal populations including hypocre-
tinergic cells, increases CART and decreases NPY expression,
consistent with its anorexic effect. However, the CB1 antagonist
has no effect in hypocretin expression suggesting that hypocretins
arenotlikelytobethemainmediatorsofcannabinoidhypothalamic
orexigenic effects (Verty et al., 2009). An interesting electrophys-
iological study in mouse reveals that the cannabinoid agonist
WIN55-212,2 depolarizes MCH cells increasing spike frequency
while reducing spontaneous firing of hypocretin cells (Huang
et al., 2007). CB1-mediated depolarization of MCH cells was a
consequence of cannabinoid action on axons arising from LH
local inhibitory cells, resulting in reduced synaptic GABA release
on MCH neurons. On the contrary, CB1 agonists hyperpolarized
hypocretin cells by presynaptic attenuation of glutamate release
(Huang et al., 2007). These results are in line with the idea that
some of the orexigenic actions of cannabinoids could be explained
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Table 1 | Studies investigating the interaction between endocannabinoid and hypocretinergic systems.
Functional
interaction
Tools Techniques Main result References
Energy balance in vivo (rat) Hypocretin-1
CB1 antagonist
Food intake monitoring Subeffective systemic rimonabant
attenuates food intake induced by
central hypocretin-1
Crespo et al.,
2008
Rat tissue CB1 antagonist LH Immunofluorescence
qRT-PCR
Western Blot
Rimonabant administration induces
Fos expression in hypocretin, MCH,
MSH and CART neurons, but does
not affect hypocretin mRNA or
protein levels
Verty et al.,
2009
ex vivo
(mouse)
Obese ob/ob mice
High-fat diet
CB agonist
Leptin
mTOR inhibitor
Confocal, electron microscopy
LH electrophysiology
LH immunofluorescence
In obesity, hypocretinergic neurons
overexpress DAGL and receive
predominantly inhibitory, instead of
excitatory, CB1-expressing inputs.
These alterations are reversed by
leptin administration
Cristino et al.,
2013
Reward and
Cannabis
dependence
in vivo (rat) Cholinergic agonist
HcrtR1 antagonist
CB1 antagonist
Conditioned place preference CPP induced by LH-chemical
stimulation requires HcrtR1 and
CB1 receptor signaling in the VTA
Taslimi et al.,
2011
in vivo
(mouse)
HcrtR1 knockout mice
CB agonists
HcrtR1 and HcrtR2
antagonists
Drug self-administration
LH immunofluorescence
In vivo microdyalisis
Rewarding properties of
cannabinoids are modulated by
HcrtR1 and activate LH
hypocretinergic neurons.
HcrtR1 regulates THC-induced
dopamine release in Nac
Flores et al.,
2013
in vivo
(human)
– Peripheral blood gene
expression and promoter
metylation study
THC-smokers show decreased
hypocretin expression when
compared to cigarette-smokers
Rotter et al.,
2012
Antinociception ex vivo and in
vivo (rat)
Hypocretin-1
HcrtR1 and HcrtR2
antagonists
CB1 agonist and antagonist
PLC and DAGL inhibitors
PAG electrophysiology
PAG Immunofluorescence
Hot plate test
Hypocretin-1 inhibits GABA release
to PAG neurons through retrograde
2-AG signaling, leading to increased
PAG activity.
Antinociceptive responses induced
by intra-PAG administration of
hypocretin-1 are mediated by
HcrtR1 and CB1 receptors
Ho et al., 2011
Sleep/wake
cycle
in vivo (rat) CB1 agonist and antagonist EEG and EMG monitoring
LH immunofluorescence
Intra-LH administration of 2-AG
increases REM sleep and cFos
expression in MCH neurons, but
does not affect cFos expression in
hypocretinergic neurons
Pérez-Morales
et al., 2013
ex vivo (rat) Hypocretin-2
CB1 agonist and antagonist
PLC and DAGL inhibitors
DRN electrophysiology Hypocretin-2 inhibits glutamate
release to DRN serotonergic
neurons through retrograde 2-AG
signaling
Haj-Dahmane
and Shen, 2005
Cellular and
molecular
interaction
ex vivo
(mouse)
CB agonist ad antagonist
GABAa antagonist
iGluR antagonist
LH electrophysiology
Immunocytochemistry
Cannabinoids reduce activity of
hypocretin neurons by presynaptic
attenuation of glutamate release
and excite MCH neurons by
presynaptic inhibition of GABA
release
Huang et al.,
2007
(Continued)
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Table 1 | Continued
Functional
interaction
Tools Techniques Main result References
in vitro (cell
culture)
Hypocretin-1
CB1 antagonist
Confocal, electron microscopy
Intracellular signaling assays
CB1-HcrtR1 coexpression
potentiates activation of the MAPK
pathway induced by hypocretin-1
Hilairet et al.,
2003
in vitro (cell
culture)
Hypocretin-1
CB1 agonist and antagonist
HcrtR1 antagonist
Redistribution assays
Epifluorescence microscopy
FRET imaging
CB1-HcrtR1 heteromerization
results in coordinated alteration of
their cellular localization and
downstream signaling
Ellis et al., 2006
in vitro (cell
culture)
CB1 agonist and antagonist
HcrtR1 antagonist
Co-immunoprecipitation
SNAP and CLIP tagging
FRET imaging
Intracellular signaling assays
Heteromultimerization of
CB1-HcrtR1 is confirmed by
co-immunoprecipitation and
SNAP/CLIP tagging.
Modulation of receptor
internalization and MAPK pathway
activation is also reproduced
Ward et al.,
2011a,b
in vitro (cell
culture)
Hypocretin-1 and -2
CB1 agonist and antagonist
DAGL and MAGL inhibitors
PLC, PLD and PLA inhibitors
HcrtR1 antagonist
Intracellular signaling assays HcrtR1 stimulation by hypocretin-1
activates PLA2 and DAGL cascades
with subsequent release of AA and
2-AG, which acts as paracrine
messenger through CB1
Turunen et al.,
2012
in vitro (cell
culture)
Hypocretin-1 and -2
CB1 antagonist
HcrtR1 antagonist DAGL and
MEK inhibitors
Intracellular signaling assays Release of 2-AG induced by
hypocretin-1 stimulates ERK
activity in neighboring
CB1-expressing cells.
HcrtR1-mediated ERK activity is
potentiated in cells coexpressing
CB1-HcrtR1
Jäntti et al.,
2013
Abbreviations: IF, immunofluorescence; EPS, electrophysiology; drug self admin, drug self-administration; EF microscopy, epifluorescence microscopy; co-IP, co-
immunoprecipitation.
by their synaptic effects on MCH neurons, which undoubtedly
regulate energy balance (Pissios et al., 2006), and are not medi-
ated by hypocretin neurons at least in physiological conditions.
However, a recent study shows that the balance between CB1-
expressing glutamatergic and GABAergic inputs to hypocretin
neurons is altered in obesity (Cristino et al., 2013). In leptin-
knockout (ob/ob) obese mice and in diet-induced obese mice,
hypocretin neurons appear to receive predominantly inhibitory
instead of excitatory CB1-expressing inputs (Cristino et al., 2013).
In addition, hypocretin neurons overexpress themain enzyme that
synthesizes 2-AG, DAGLα, in these obesity models, in line with
previous results reporting elevated hypothalamic levels of endo-
cannabinoids in ob/obmice andobeseZucker rats (DiMarzo et al.,
2001). These alterations could result in a retrograde inhibition of
these inhibitory CB1-expressing axon terminals, leading to dis-
inhibition of hypocretinergic neurons and enhancing hypocretin
innervation of target brain areas. This remodeling could be a
consequence of leptin signaling impairment, since it was reversed
by the systemic administration of leptin (Cristino et al., 2013).
Therefore, in these pathological conditions, hypocretins could
exacerbate obesity as a result of an increased hypocretin release
in the hypothalamus, leading to hyperphagia and sleep disorders
(Alpár and Harkany, 2013).
Another relevant integrative region in the control of appetite
is the nucleus of the solitary tract (NTS) in the hindbrain, which
regulates individual meal sizes and the intervals between meals
(Valassi et al., 2008). Peripheral satiety signals are relayed to
the NTS via vagal afferent neurons, whose cell bodies lie in the
nodose ganglia. It has been recently reported that fasting-induced
increase in CB1 immunoreactivity has been observed under stan-
dard food regime in the nodose ganglia (Cluny et al., 2013). In
contrast, OX-1R immunoreactivity is modified by fasting only
in rats exposed to high-fat diet, denoting a differential regula-
tion of these neurotransmitter systems in this structure (Cluny
et al., 2013). On the other hand, hypocretin-1 depolarizes NTS
neurons through regulation of non-selective cationic and K+
conductances in a PKC-dependent manner (Yang et al., 2003;
Yang and Ferguson, 2003). It has ben also reported that CB1
receptor activation modulates NTS neuronal activity (Seagard
et al., 2005; Endoh, 2006). However, it remains to be investi-
gated whether these neurochemical effects in nodose ganglia and
NTS are relevant in the control of feeding behavior, and if there
exists an interplay between endocannabinoid and hypocretinergic
mechanisms.
Endocannabinoid and hypocretinergic systems seem to play
antagonistic roles in the peripheral control of energy balance.
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FIGURE 3 | Schematic representation of the main brain pathways
involved in the homeostatic control of food intake. Ghrelin released
during fasting from stomach and leptin from adipose tissue, among other
mediators, bind to receptors on orexigenic and/or anorexigenic neurons in
the ARC of the hypothalamus. This induces the release of either the
orexigenic neuropeptides NPY and AgRP or the anorexigenic neuropeptides
CART and the POMC-derived peptide α-MSH. These neuropeptides from
the ARC travel along axons to secondary neurons in other areas of the
hypothalamus such as the PVN and the LH. The ultimate effects of these
signaling cascades are changes in the sensation of hunger and satiety in
the NTS. Hypocretinergic and MCH neurons are modulated differently by
inhibitory or excitatory CB1-expressing inputs. ARC, arcuate nucleus; PVN,
paraventricular nucleus; LH, lateral hypothalamus; NTS, nucleus of the
tractus solitarius; 3V, third ventricle; NPY, neuropeptide Y; AgRP,
Agouti-related peptide; CART, cocaine- and amphetamine-regulated
transcript; POMC, pro-opiomelanocortin; MCH, melanin-concentrating
hormone; CRH, corticotropin-releasing hormone; Hcrt1, hypocretin-1;
Hcrt2, hypocretin-2.
The reduction of body weight and fat mass exerted by CB1
antagonists in diet-induced obesity models is partially due to the
counteraction of a peripheral stimulation of lipogenesis by endo-
cannabinoids (Di Marzo and Matias, 2005). Moreover, chronic
CB1 blockade improves peripheral metabolic parameters of obe-
sity, including a reduction in plasma levels of insulin and leptin.
In contrast, mice overproducing the hypocretin peptides exhibit
resistance to high-fat diet-induced obesity at least in part by pro-
moting energy expenditure (Tsuneki et al., 2010). These antiobe-
sity metabolic effects have been demonstrated to be mediated by
HcrtR2, which has been observed to improve leptin sensitivity
(Funato et al., 2009). However, no studies have been yet published
assessing whether endocannabinoid and hypocretinergic systems
show a cross-modulation in their peripheral control of metabolic
rates.
REGULATION OF THE BRAIN REWARD SYSTEM
Endocannabinoid and hypocretinergic systems are also involved
in the regulation of the mesocorticolimbic rewarding system, a
circuit responsible for the pleasurable feelings associated with
natural rewards and the consumption of drugs of abuse. The
major components of this reward circuit are the VTA, which
contains the dopaminergic cell bodies, and its target areas, includ-
ing the NAc, amygdala, frontal and limbic cortices (Wise, 2004).
CB1 and HcrtRs receptors are abundant in the brain reward
circuitry and participate in the rewarding properties of natu-
ral rewards and also in those induced by different drugs of
abuse (Maldonado et al., 2006). Acting as a retrograde messen-
ger, endocannabinoids modulate the glutamatergic excitatory and
GABAergic inhibitory synaptic inputs into the dopaminergic neu-
rons of the VTA and the glutamate transmission in the NAc.
Thus, the activation of CB1 receptors present on axon terminals
of GABAergic neurons in the VTA inhibits GABA transmission,
removing this inhibitory input on dopaminergic neurons (Riegel
and Lupica, 2004). Glutamate synaptic transmission in the VTA
and NAc, mainly from neurons of the PFC, is similarly modulated
by the activation of CB1 receptors (Melis et al., 2004). The final
effect of endocannabinoids on the modulation of dopaminergic
activity, which depends on the functional balance between these
GABAergic and glutamatergic inputs, is predominantly excita-
tory (Maldonado et al., 2006). On the other hand, hypocretins
regulate reward seeking also by modulating VTA dopaminergic
transmission. In agreement, intra-VTA infusion of hypocretin-1
and -2 increased dopamine release in NAc and PFC as mea-
sured by microdialysis or voltammetry (Vittoz et al., 2008; España
et al., 2011). Hypocretins elicit their influence on VTA dopamine
cell firing not only via direct depolarization of dopamine neu-
rons (Korotkova et al., 2003), but also interacting with other
neurotransmitters within the VTA, such as glutamate (Borgland
et al., 2006). Thus, intra-VTA infusion of hypocretin-1 increased
both glutamate and dopamine release, which was attenuated by
the AMPA/NMDA antagonist kynurenic acid, suggesting that
hypocretin has a profound influence on dopamine neurons by
affecting glutamatergic activity (Wang et al., 2009). Hypocretin-1
enhanced glutamatergic synaptic strength on dopamine neurons
in VTA slices (Borgland et al., 2006). In accordance, the control
of this limbic structure by the PFC projections was improved by
hypocretin-1 in rats (Mahler et al., 2013).
This considerable modulation of the reward circuit by endo-
cannabinoid and hypocretinergic systems reveal their important
role in the non-homeostatic control of food intake. CB1 recep-
tor antagonists have been reported to reduce the conditioned
place preference (CPP) for food (Chaperon et al., 1998), and the
motivation for food in a progressive ratio schedule of food self-
administration in rats (Gallate and McGregor, 1999). According
to this, null mutant CB1 mice show a reduced motivation to
work for food compared to wild-type littermates (Sanchis-Segura
et al., 2004). CB1 receptor blockade also decreases the reinforc-
ing properties of chocolate and sweets (Maccioni et al., 2008). In
addition, intra-NAc injections of anandamide enhance the reward
associated with sweets (Mahler et al., 2007). Similarly, several
data support a role for hypocretins in food-seeking and taking.
Thus, chronic administration of the HcrtR1 antagonist SB334867
altered standard food self-administration in food-restricted mice
(Sharf et al., 2010), although this effect was not observed in rats
after acute administration of the HcrtR1 antagonist (Borgland
et al., 2009). Indeed, it seems that hypocretinergic control of food-
related reward is more relevant when it involves particularly palat-
able foods (Mahler et al., 2012). In agreement, SB334867 reduces
both motivational and primary reinforcing effects in rats trained
to self-administer high-fat food, both under food-restriction or
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satiation (Nair et al., 2008; Choi et al., 2010). So far, no studies
have investigated if endocannabinoid and hypocretinergic sys-
tems have common mechanisms in the modulation of natural
reward. However, it seems that both neurotransmitter systems
regulate food intake especially when particularly palatable/or
salient food is involved or higher effort is required to obtain this
natural reinforcer.
Similarly, the addictive properties of several drugs of abuse
are modulated by hypocretinergic and endocannabinoid systems.
Hypocretin transmission regulates the primary reinforcing effects
of opioids (Narita et al., 2006; Smith and Aston-Jones, 2012),
nicotine (Hollander et al., 2008; LeSage et al., 2010) and alco-
hol (Lawrence et al., 2006; Moorman and Aston-Jones, 2009).
However, the involvement of the hypocretin system in the reward-
ing properties of psychostimulants seems to be relevant only
under conditions that require a high effort to obtain the drug
(Boutrel et al., 2005; España et al., 2011). This distinct reg-
ulation could be due to differences among the mechanism of
action by which these drugs of abuse alter the mesolimbic func-
tion (Plaza-Zabala et al., 2012). Opioids, nicotine and alcohol
increase extracellular levels of dopamine in the NAc by enhancing
dopaminergic firing rates in the VTA, whereas psychostimulants
directly inhibit dopamine uptake in the NAc (Di Chiara et al.,
2004). Thus, rewarding effects of drugs of abuse that depend
on increased VTA dopaminergic activity may require hypocre-
tinergic transmission, as the VTA appears to be an essential site
of action for hypocretins to modulate these effects. In contrast,
the mechanism of action of psychostimulants avoids this critical
site of action of hypocretins. Intriguingly, a similar phenomenon
occurs with the modulatory role of the endocannabinoid system
on the primary rewarding effects of drugs of abuse. Thus, opi-
oid (Navarro et al., 2001, 2004), cannabinoid (Maldonado et al.,
2006), nicotine (Castañé et al., 2002; Cohen et al., 2002) and
alcohol (Hungund et al., 2003; Wang et al., 2003) reinforcement
depend on endocannabinoid signaling in the VTA, but primary
rewarding effects of psychostimulants remain unaffected in the
absence of CB1 receptors (Martin et al., 2000; Soria et al., 2005).
However, the endocannabinoid system is important for main-
taining psychostimulants seeking behavior when higher effort is
required to obtain the drug, probably by the modulation of other
mechanisms independent from release of dopamine in the NAc
(Soria et al., 2005). It has been recently reported that CPP induced
by chemical stimulation of the LH with the cholinergic agonist
carbachol is regulated by HcrtR1 activation in the VTA. Thus,
unilateral intra-VTA administration of the HcrtR1 antagonist
SB334867 dose-dependently inhibited this behavioral response
(Taslimi et al., 2011). Interestingly, intra-VTA administration of
rimonabant also decreased CPP induced by LH-stimulation in
a dose-dependent manner. Co-administration of effective doses
of both HcrtR1 and CB1 antagonists into the VTA reduced CPP
in a non-additive manner, suggesting that these receptors regu-
late this effect by a common mechanism (Taslimi et al., 2011).
Nevertheless, future experiments showing the specific location
of HcrtR1 and CB1 receptors within the VTA neurons will be
necessary to better understand the interaction between the endo-
cannabinoid and hypocretin systems in the regulation of the
reward circuit.
A relevant but almost unexplored aspect of hypocretin-
cannabinoid interplay is the role of the hypocretinergic system
in the addictive properties of cannabinoids, whose recreational
use has progressively increased in developed countries in the last
decade (Murray et al., 2007). Therefore, the identification of new
therapeutic targets to improve treatment outcomes for cannabis
dependence is imperative considering that no effective pharma-
cotherapeutic approaches for this disorder are currently available.
Although operant responding for self-infused THC has not been
consistently reported in rodents, intravenous self-administration
of the synthetic cannabinoid WIN55,212-2 has been observed
in rats and mice (Fattore et al., 2001; Mendizábal et al., 2006).
The reinforcing properties of cannabinoids have been related to
their capability to enhance dopamine extracellular levels in the
NAc shell (Fadda et al., 2006; Lecca et al., 2006), although other
neurochemical systems have also been involved in cannabinoid
reward, such as opioid, noradrenaline, serotonine, acetylcholine
and adenosine systems (Maldonado et al., 2011).
Recently, the hypocretinergic system has also been reported to
contribute to cannabinoid-induced reward. Indeed, genetic dele-
tion or pharmacological blockade of HcrtR1 reduced the reinforc-
ing effects of WIN55,212-2, as revealed by impaired intravenous
self-administration of this synthetic cannabinoid in mice (Flores
et al., 2013). In contrast, the HcrtR2 antagonist TCSOX229 had
no effect in these behavioral responses. The enhancement in
dopamine extracellular levels in the nucleus accumbens induced
by THC was also blocked in mice lacking the HcrtR1, sug-
gesting that cannabinoids require hypocretinergic transmission
to induce dopamine release in the NAc. Moreover, contingent
WIN55,212-2 self-administration, but not passive exposure to
the cannabinoid, increased the percentage of hypocretin neurons
expressing FosB/FosB in the LH, revealing that this activation
was mainly due to operant seeking for the reinforcing effects
of this drug and not to its pharmacological responses (Flores
et al., 2013). Cannabinoid-induced activation of hypocretin neu-
rons reported in this study differs from previous electrophys-
iological data supporting that cannabinoids inhibit hypocretin
neurons by CB1-mediated attenuation of glutamate release in
these cells (Huang et al., 2007), but possible clarification of this
divergence has recently emerged. As previously mentioned, a
switch in CB1-mediated control of GABAergic and glutamater-
gic inputs is observed in obese mice (Cristino et al., 2013). It
is thus reasonable that if this synaptic remodeling takes place in
determined pathological conditions, such as obesity, the devel-
opment of drug addiction might entail similar consequences
by different mechanisms. However, this possibility still remains
to be elucidated. Other recent evidence supports the relation-
ship between hypocretins and cannabis dependence. It has been
reported that hypocretin-1 expression in peripheral blood cells
is modified in cannabis-dependent smokers when compared to
nicotine-dependent smokers and non-smokers (Rotter et al.,
2012). However, these data provide poor functional informa-
tion, as peripheral hypocretin mRNA levels do not necessar-
ily reflect the situation in the CNS. Moreover, it is likely that
these differences are more related to peripheral actions of THC
and not to the central effects involved in the development of
dependence.
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NOCICEPTION
Analgesia is one of the main therapeutic targets of cannabi-
noids. CB1 receptors are highly expressed in pain transmission
and modulation regions such as PAG, rostroventral medulla
(RVM), spinal cord and primary afferent fibers (Hohmann and
Suplita, 2006). Consistent with this anatomic location, several
animal studies demonstrated that both endogenous and exoge-
nous cannabinoids produce antinociceptive effects in different
animal models mainly through the activation of CB1 recep-
tors (Martin et al., 1993; Herzberg et al., 1997; Dogrul et al.,
2002). Moreover, CB2 receptors have been reported to contribute
to antinociception in some chronic pain models (Racz et al.,
2008; La Porta et al., 2013). Cannabinoid-mediated antinoci-
ception takes places at peripheral, spinal and supraspinal levels.
One of the best characterized mechanisms of pain modulation
is the descending inhibitory pathway. This descending modula-
tory mechanism originates in the PAG, which activates neurons
in the RVM, the main relay station between the PAG and spinal
cord. RVMneurons send inhibitory projections to the dorsal horn
of the spinal cord via dorsolateral funiculus (DLF) and modu-
late pain perception at the spinal level (Ren and Dubner, 2008).
The demonstration that cannabinoid antinociceptive effects are
diminished following surgical DLF lesion provides evidence that
descending pain modulatory pathways play a crucial role in these
responses (Lichtman and Martin, 1991). Thus, microinjection
of the cannabinoid agonists HU210 and WIN55,212-2 into the
PAG elicits antinociception mediated by CB1 receptor activa-
tion (Lichtman et al., 1996; Finn et al., 2003). This effect is the
result of disinhibition of GABAergic output neurons in the PAG
that leads to activation of descending inhibitory pain pathways
(Vaughan et al., 2000). Similarly, local injection of CB1 ago-
nists into RVM had antinociceptive effects due to presynaptic
inhibition of GABAergic tone (Vaughan et al., 2000). Moreover,
anandamide and 2-AG levels were increased in RVM in some
models of chronic pain, presumably as an adaptive mechanism
to counteract pain transmission (Petrosino et al., 2007).
Antinociceptive effects of hypocretins have been shown in
several pain models (Chiou et al., 2010). Thus, hypocretin-1
administration by central or systemic route reduces the noci-
ceptive responses in mice in response to thermal, mechanical
and chemical stimuli (Mobarakeh et al., 2005). Hypocretin-
2 has also been reported to induce antinociceptive effects in
some pain models, but with lower potency than hypocretin-
1 (Mobarakeh et al., 2005). Hypocretin-induced antinocicep-
tion seems to be mainly mediated by HcrtR1, as revealed by
using selective antagonists (Bingham et al., 2001). Hypocretin-
containing fibers and HcrtRs are densely distributed in several
regions of the CNS involved in the regulation of pain, includ-
ing the PAG and spinal dorsal horn (Peyron et al., 1998; Marcus
et al., 2001). Like cannabinoids, hypocretins appear to modu-
late pain perception at both spinal and supraspinal levels, but
the mechanism of action remains unclear. The midbrain PAG is
one of the possible supraspinal sites of hypocretin antinocicep-
tion. Interestingly, PAG c-fos expression was elevated following
central hypocretin administration (Date et al., 1999). In agree-
ment, microinjection of hypocretin-1 into the PAG reduced hot-
plate nociceptive responses in mice (Lee and Chiou, 2009) and
formalin-induced nociceptive behaviors in rats (Yamamoto et al.,
2002). A recent study in PAG slices revealed that hypocretin-
1 induces inhibition of GABAergic transmission, producing an
overall excitatory effect on evoked postsynaptic potentials and
hence increasing PAG neuronal activity (Ho et al., 2011). This
effect was blocked by the HcrtR1 antagonist SB334867, but not
by the HcrtR2 antagonist TCSOX229. Moreover, the CB1 antag-
onist AM251 reversed the effect of hypocretin-1. Administration
of U73122 and tetrahydrolipstatin, inhibitors of PLC and DAGL
respectively, blocked the inhibition of GABAergic tone induced by
hypocretin-1, while the inhibitor of the enzymatic degradation
of 2-AG, URB602, enhanced this hypocretin effect. Therefore,
hypocretin-1 may produce antinociception in part by activating
postsynaptic HcrtR1 receptors and stimulating synthesis of 2-AG
through a PLC–DAGL enzymatic cascade, culminating in retro-
grade inhibition of GABA release in the PAG. The in vivo existence
of such analgesic mechanism was confirmed by systemic admin-
istration of SB334867 and AM251 after intra-PAGmicroinjection
of hypocretin-1, which almost fully reversed the antinocicep-
tive responses in the hot-plate test in rats (Ho et al., 2011).
Importantly, this 2-AG-mediated antinociception induced by
hypocretin signaling may contribute to stress-induced analgesia,
since hypocretins have been reported tomodulate this response to
stress (Watanabe et al., 2005; Xie et al., 2008) and endocannabi-
noids within the PAG are also believed to be involved in this
effect (Hohmann and Suplita, 2006). Therefore, under stressful
conditions, activation of HcrtR1 may lead to PAG stimulation
and produce analgesia through 2-AG via the CB1–PLC–DAGL
cascade.
Both endocannabinoid and hypocretinergic systems exert also
antinociceptive effects at the spinal (Drew et al., 2000; Grudt
et al., 2002) and peripheral levels (Millns et al., 2001; Yan et al.,
2008), but no data are available regarding a possible contribution
of endocannabinoids in spinal or peripheral hypocretin-induced
analgesia. Moreover, the possible modulation of cannabinoid-
induced antinociception by hypocretins has not been studied yet.
SLEEP/WAKE CYCLE
Several data indicates that the hypocretinergic system is involved
in the regulation of sleep-wake cycle. Thus, hypocretin neurons
fire at maximal rate in wakefulness and remain silent in rapid
eye movement (REM) sleep (Lee et al., 2005). Likewise, phar-
macological stimulation of the hypocretinergic system increases
wakefulness and reduces REM sleep (Akanmu and Honda, 2005).
Accordingly, the dysfunction of this system is linked to narcolepsy,
as revealed in dogs with mutated HcrtR2 gene and mice lacking
hypocretins or HcrtR2 (Lin et al., 1999; Willie et al., 2003). On
the other hand, endocannabinoids are also involved in sleep reg-
ulation and have been shown to be strong sleep-inducers (Cravatt
et al., 1995). Besides, systemic administration of rimonabant
increases wakefulness and decreases REM sleep in rats (Santucci
et al., 1996), whereas acute (Murillo-Rodríguez et al., 2001),
subchronic (Herrera-Solís et al., 2010) and intrahippocampal
(Rueda-Orozco et al., 2010) administration of anandamide has
the opposite effect.
Few studies have investigated the possible mechanisms shared
by the hypocretinergic and endocannabinoid systems in the
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regulation of sleep and wakefulness. The finding that cannabi-
noid signaling leads to hyperpolarization of hypocretin neurons
and depolarization of MCH neurons in in vitro preparations
(Huang et al., 2007) encouraged the idea that endocannabinoids
could interact with these hypothalamic neurons to regulate sleep.
Indeed, intra-hypothalamic administration of 2-AG increases
REM sleep in rats through CB1 receptor and MCH signaling,
since 2-AG slightly decreased c-fos expression in hypocretin neu-
rons and activated MCH neurons (Pérez-Morales et al., 2013).
Endocannabinoid and hypocretinergic systems could be involved
in the modulation of sleep/wake cycle by acting in dorsal raphe
nucleus (DRN) serotonergic neurons, closely linked to REM
sleep and arousal. Thus, these neurons discharge at a high fre-
quency during waking, at a lower rate during non-REM sleep
and become silent during REM sleep (McGinty and Harper,
1976; Portas et al., 1996). Activation of HcrtRs increases activ-
ity of DRN serotonergic neurons (Brown et al., 2001; Liu et al.,
2002). However, an electrophysiological study performed in rat
DRN slices has reported that hypocretin-2 also inhibits glu-
tamatergic transmission to serotonergic neurons of the DRN
via retrograde endocannabinoid messengers (Haj-Dahmane and
Shen, 2005). Although the functional implications of this ret-
rograde synaptic modulation are not clear, the authors propose
that it could prevent excessive excitation of DRN serotonergic
neurons to provide a homeostatic control, contributing to the
stable firing activity of these arousal-related neurons. Therefore,
the loss of the hypocretin signal could lead to the disorga-
nized activity and fragmented wakefulness observed in narcolepsy
(Haj-Dahmane and Shen, 2005). However, further studies should
be carried out to clarify the relevance of the possible interac-
tions between cannabinoid and hypocretinergic systems in sleep
modulation.
CONCLUDING REMARKS
The existence of a cross-talk between the hypocretinergic and
endocannabinoid systems is strongly supported by their partially
overlapping anatomical distribution and common role in sev-
eral physiological and pathological processes. However, little is
known about the mechanisms underlying this interaction. The
formation of heteromers between HcrtR1 and CB1 receptors has
been demonstrated in vitro, which alters the cellular localiza-
tion and downstream signaling of both receptors. However, the
biological significance of these heteromers remains unknown,
and further studies are needed to verify whether the two recep-
tors are expressed on the same target neurons and if they form
heteromers in vivo. In this regard, better tools should be devel-
oped to determine the specific location of HcrtRs due to the
cross-reactivity problems of the currently available antibodies
(Kukkonen, 2012). On the other hand, hypocretin signaling
has been reported to stimulate the synthesis of 2-AG leading
to retrograde inhibition, which suggests that endocannabinoids
might contribute to several hypocretin effects. Recent evidence
denotes that this endocannabinoid-mediated retrograde inhibi-
tion is present in diverse brain regions in vivo, being of spe-
cial relevance in the regulation of the analgesic effects induced
by hypocretins. Interesting data also point to a collaboration
of endocannabinoid and hypocretinergic systems in the central
control of food intake and obesity. The hypocretinergic trans-
mission is overstimulated in this pathological condition, and
HcrtR antagonists might be useful in the control of appetite
and other disorders associated with obesity, such as anxiety and
sleep deregulations. However, the apparent antiobesity role of
HcrtR2 in the peripheral control of energy balance should be
taken into account and would possibly require the use of selec-
tive HcrtR1 antagonists for this specific purpose. Blockade of
HcrtR1 signaling has demonstrated also its therapeutic potential
against cannabinoid dependence by interfering with the reward-
ing effects of this drug. Nevertheless, the variety of hypocretin
and endocannabinoid signaling implies that their manipulation
to regulate a specific physiological process would probably pro-
duce several side effects. To avoid this problem, efforts should
be focused on the development of selective agonists/antagonists
for the different receptors and/or with site specific activity.
Some authors defend that diverse GPCR heteromers are disease-
specific and/or exhibit unique tissue specificity (Gomes et al.,
2013). If this would be the case of CB1-HcrtR1 heteromers,
they would serve as ideal drug targets with potentially lesser
side effects that the single receptors. Although research about
the cannabinoid-hypocretinergic interplay has only taken the
first steps, future investigation in this field will lead to a bet-
ter understanding of the therapeutic potential of this interesting
interaction.
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